BASEL, Switzerland, June 8, 2026
Novartis announced the presentation of data from 10 scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, showcasing the potential of Rhapsido® (remibrutinib) across multiple immune-mediated diseases. Key presentations include results from the pivotal Phase III RemIND trial in chronic inducible urticaria (CIndU), long-term extension data from the Phase IIIb REMIXED study in chronic spontaneous urticaria (CSU), and Phase II findings in adults with IgE-mediated peanut allergy. The data further strengthen the growing evidence supporting BTK inhibition as a promising therapeutic approach in allergic and inflammatory disorders.
Phase III Studies Demonstrate Strong Efficacy in Urticaria
One of the major highlights at EAACI 2026 is the late-breaking presentation of the Phase III RemIND study, the largest clinical trial conducted in chronic inducible urticaria. The study demonstrated that Rhapsido (remibrutinib) achieved superior efficacy compared with placebo while maintaining a favorable safety profile in patients with different forms of chronic inducible urticaria. In addition, data from the Phase IIIb REMIXED extension study showed sustained efficacy and continued safety benefits in patients with chronic spontaneous urticaria, supporting the long-term treatment potential of remibrutinib in managing difficult-to-treat urticaria conditions.
Food Allergy and Biomarker Data Expand Clinical Potential
Novartis is also presenting Phase II research evaluating remibrutinib in adults with IgE-mediated peanut allergy, including dose-response analyses and oral food challenge outcomes. These findings provide early evidence that BTK inhibition may have applications beyond urticaria and could potentially address significant unmet needs in food allergy management. Additional analyses revealed that remibrutinib-induced reductions in B-cell biomarkers were associated with complete and sustained responses in chronic spontaneous urticaria patients, further supporting the drug’s mechanism of action and clinical effectiveness.
Advertisement
Broader Research Highlights Unmet Needs in Allergy Care
Beyond clinical trial data, Novartis is presenting multiple real-world evidence studies focused on patient burden, treatment experiences, and healthcare challenges associated with chronic urticaria. These include findings from the global REASSERT study, physician and patient surveys from China under the Urticaria Voices initiative, and analyses from the CURE Registry examining unmet treatment needs. Together, these studies provide valuable insights into disease burden, quality of life impacts, and opportunities to improve patient care. Novartis stated that the growing body of evidence presented at EAACI 2026 reinforces the potential of Rhapsido to address significant unmet medical needs across a range of immune-mediated diseases while expanding the therapeutic possibilities of BTK inhibition.
Source: Novartis press release
